NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the Duke University Medical Center, affiliated with Duke University, Durham, North Carolina, will serve as a clinical site for Pluristem’s Phase-I clinical trial involving PLX-PAD for patients with critical limb ischemia (CLI).
